Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combivent vs. Salbutamol for Metacholine Induced Bronchospasm
NCT02182713Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 1998
- Primary completion
- Sep 1998
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of ipratropium bromide in asthma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Provocative Dose causing 20% fall in FEV1. Started May 1998; status: completed.
02
Drugs
ipratropium bromide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02182713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182713.